In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells

In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells in Healthy Subjects Using Stable Isotope Resolved Metabolomics: A Pilot Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03384108

Enrollment

Registered

2017-12-27

Start date

2017-09-01

Completion date

2028-01-01

Last updated

2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This pilot study will first establish the feasibility of an in vivo methodology of assessing the utilization of glutamine into the TCA cycle of normal bone marrow plasma cells from healthy subjects while comparing it to an ex vivo approach

Detailed description

Twenty healthy adult study participants between the ages of 18 and 60 years will be recruited to participate in this pilot study that will include two groups: a) Ex Vivo group (10 volunteers) and b) In Vivo group (10 volunteers). Volunteers will be recruited to either group in a sequential alternating fashion. In vivo 13C SIRM studies evaluating the utilization of glutamine into the TCA cycle of normal bone marrow plasma cells.

Interventions

OTHER5-13C-Glutamine

Intravenous infusion of 5-13C-Glutamine

OTHERBone marrow aspiration

Bone marrow aspiration of bone marrow aspirate

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

In Vivo vs. Ex Vivo assessment of 5-13C-Glutamine incorporation by plasma cells via a bone marrow aspiration.

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Ages 18-60 * Able to provide written consent

Exclusion criteria

* Renal Failure * Pregnancy * Active steroid use * Active liver Disease * Anemia (Hemoglobin \< 12.5 g/dL in men and \< 11.5 g/dL in women) * H/O alcohol use (average \> 2 drinks per day) * BMI \> 30

Design outcomes

Primary

Measure	Time frame	Description
Percentage of enrichment of 13-Carbon molecules in the TCA cycle metabolites of plasma cells measured by gas chromatography mass spectrometry.	Through study completion, an average of 1 hour	The plasma cells obtained from the bone marrow aspiration will be processed to determine the percent of 13-carbon enrichment in the various molecules of the TCA cycle within the plasma cells. The outcomes will be reported as a percentage. E.G. 5% of glutamine is labeled with 13-Carbon; e.g. 4% of glutamate is labeled with 13-carbon etc.

Countries

United States

Contacts

CONTACTWilson Gonsalves

gonsalves.wilson@mayo.edu5072842511

PRINCIPAL_INVESTIGATORWilson Gonsalves, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026